Therapeutic Response

v::ALK status confers therapeutic sensitivity to Atezolizumab in combination with Bevacizumab, Carboplatin, and Paclitaxel in patients with Non-Small Cell Lung Cancer.

Statements

Source and description

Tecentriq (atezolizumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, atezolizumab, in combination with bevacizumab, paclitaxel, and carboplatin, is indicated only after failure of appropriate targeted therapies.